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INTRODUCTION 
 
 
 Since the first appearance of Tuberculosis in humans probably some 8000 
years ago its control has continued to elude the brightest minds and to challenge both 
the human and economic resources of the countries around the world. Several authors 
have estimated the magnitude of the problems in the last two decades. All these 
publications represent estimates but they all indicate very clearly that Tuberculosis is 
still one of the major killer diseases in the world wide. 
 
 It is estimated that one third of the worlds population (1.7 billion) are infected 
with Mycobacterium Tuberculosis. 1% of the worlds population are infected every 
year among these 95% of the affected individuals are in developing countries and 
98% deaths due to Tuberculosis are also found to be in developing countries. These 
deaths accounts for 25% of all avoidable deaths in developing countries. Among the 
affected people 75 % are in the economically productive age. 
 
 India has 28.4 % of entire world’s Tuberculosis burden. Every second one 
Indian above the age of 20 years is infected. There are about 14 million cases among 
which 3.5 million are sputum positive. Every year 2.2 Million people contact 
Tuberculosis. One Indian dies every minute which accounts for 5 lakhs per year. 
 
 Estimates of prevalence of drug resistance in the community will be useful for 
formulating policies of the treatment with highly effective regiments to ensure cure 
and good drug compliance by patients and prevent emergence of drug resistance. 
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Drug resistance Tuberculosis adds to the burden of illness in the community with the 
several constraints in the managements of patients. Highly efficacious treatment 
regimens utilizing drugs that have not been prescribed previously and known to 
possess good anti-mycobacterial activity need to be employed which could increase 
the operational costs in terms of drugs monitoring of toxicity to drugs and supervision 
of administration of drugs to ensure drug regularity. 
 
 Though the efficacy of chemotherapy in the treatment of pulmonary 
tuberculosis is well established, its application on a mass scale under the domicillary 
treatment programme leaves much to be desired because of the operational 
difficulties. With the consequent irregularity of treatment one would expect a 
substantial increase of excretors of drug resistant bacilli in the community. The level 
of primary drug resistance provides an epidemiological parameter to assess the 
amount of drug resistant bacillary transmission in the community. 
 
 Mycobacterium tuberculosis can develop resistance to all known anti 
tuberculosis drugs. Emergence of drug resistance to most potent drugs like 
Streptomycin and Isoniazid could be avoided by the judicious combinations of drugs 
with proven efficacy. Wide spread practice of prescribing monotherapy, inadequate 
chemotherapy, non implementation of highly efficacious treatment regimens and poor 
drug compliance by patients could give rise an increase in the number of patients with 
drug resistant Tuberculosis. This is a matter of GLOBAL concern, and more so for 
developing countries with limited resources. Further more a high prevalence of drug 
resistance could have a significant impact on the epidemiological profile of disease 
with an increase in the proportion of drug resistance Tuberculosis in the infector pool. 
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AIM OF THE STUDY 
  
 
 
 
 
 
 
 
 
 Evaluating drug resistance profile among patients reporting at institute of 
Thoracic Medicine Chennai with sputum positivity after taking cat II under RNTCP 
and either failed/relapsed or defaulted from category II. 
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REVIEW OF LITERATURE 
 
 
DRUG RESISTANCE  
 
 
 By sensitive strains one means those strains of Tubercle bacilli which 
normally respond to low concentration of the drugs in a uniform manner. In contrast 
resistant strains are those which can grow in higher concentrations of the drug and 
they are therefore definitely different from sensitive strains. According to Dr. D.A. 
Mitchison 1961 resistance can be defined as a decrease of sensitivity to the drug of 
sufficient degree to be reasonably certain that the strain obtained is different from a 
sample of wild strains of tubercle bacilli of human type that have never come in 
contact with the drug.  
 
 The proportions of these drug resistant mutants are very small in wild strains 
that are not exposed to drugs. The definition of drug resistance of Mycobacterium 
tuberculosis was adopted by the international group of specialists assembled by the 
World Health Organization (WHO) in 1969. This definition was established by 
testing a large number of wild strains against three drugs available at that time and 
minimal inhibitory concentrations (MIC) of these drugs where established in Starch 
Free Lowenstein Jensen (LJ) medium. It was suggested that a strain would be 
considered resistant if one percent or more of the bacterial population was resistant 
to a designated concentration of drug.  
 With the introduction of Streptomycin for the treatment of tuberculosis 
Youmans and co-workers found that there was a striking clinical improvement 
along with a rapid decrease in the number of bacilli in the sputum. However the 
number of bacilli soon started increasing and the condition of the patient 
 
8
deteriorated. These investigators found that bacilli isolated from the patients were 
resistant to higher concentration of the drug. 
 
 Pyle showed that during treatment with streptomycin alone the proportion of 
drug resistant bacilli increased progressively from about 1 in 88,750 organisms 
before therapy to about 1 in 367 after 15 weeks of treatment. Crofton and Mitchison 
showed that with monotherapy or inadequate therapy the number of sensitive bacilli 
decreased while the resistant bacilli increased in lung cavities of the patient. This 
was called the   “Fall and Rise“ phenomenon. 
 
 G. Canneti stated in 1965, bacterial resistance is as old as antituberculosis 
chemotherapy approximately 20 years. A glance chronologically shows that the 
bulk of our present knowledge atleast in its basic aspects was gained within the first 
ten years and that relatively little has been added since that.  
 
 While there was some disagreement about the value of susceptibility testing of 
the initial isolates there was no doubt about the importance of testing the isolates 
obtained during the course of chemotherapy. 
 
1. If a patient does not respond clinically to treatment within a few 
months. 
2. If sputum did not convert to smear negative within 2 – 3 months of 
treatment. 
3. If the culture did not convert to negative within 4 – 6 months. 
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4. If there is an increase in the number of  bacilli in the sputum after an 
initial decrease. 
5. In case of clinical relapse. 
 
TERMINOLOGY OF DRUG RESISTANCE 
Drug Resistance in Tuberculosis could be classified as  
1. Primary. 
2. Acquired 
3. Initial. 
4. Natural 
 A wild strain is defined as a strain of Mycobacterium tuberculosis which has 
never been exposed to any anti mycobacterial drug. 
1.  Primary Resistance 
 Primary resistance is that which has not resulted from  the treatment of the 
patient with the drug concerned. It includes resistance in wild strains which 
have never come in to contact with the drug and the resistance occurring as a 
result of  exposure of a strain to the drug but in another patient.  
 
2. Acquired Resistance 
Acquired resistance is that which results from exposure of the strain to the 
drug and consequent selecting out of resistant mutant bacilli.  
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3. Initial Resistance 
 
 Initial resistance is the resistance in patients who give a history of never 
having received chemotherapy in the past it includes primary resistance and 
resistance to previous treatment concealed by  the patient or of which he was 
unaware. 
 
4. Natural Resistance 
 Natural resistance is that resistance in wild strain which have never come in 
contact with the drug such as Mycobacterium  bovis resistant to Pyrazinamide, 
Mycobacterium tuberculosis resistant  to Penicillin, Mycobacterium africanum 
resistant to Thiacetazone.  Wild type resistance is the result of random 
mutation in naturally susceptible strain before any exposure to antituberculosis 
drugs. 
 
MECHANISM OF DRUG RESISTANCE 
 
 The drug resistance in mycobacterium tuberculosis occurs by random 
spontaneous mutations of bacterial chromosomes which occur at a constant but very 
low frequency. This varies for different antituberculosis drugs. The probability of 
mutation of drug resistance is directly proportional to the size of the bacterial 
population. The development of resistance to isoniazid and streptomycin in 
mycobacterium tuberculosis occurs as a single step mutation.  
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 David et-al, calculated mutation rates for many drugs using fluctuation 
analysis. The mutation rates are very low for most of the drugs and the mutants 
resistant to one of the several antituberculosis drugs appear once in every 107   cells. 
Thus emergence of the drug resistance is due to the selection of  pre-existing 
resistance mutants in the original bacterial population. In clinical practice 
combinations of two or more antituberculosis drugs are given to the patients in order 
to eliminate all mutants resistant to any of the drugs.  
 
 The rates of spontaneous resistance are 1 in 106 organisms for Isoniazid, 1 in 
108 for Rifampicin, and 1 in 106 for Ethambutol and 1 in 105 for streptomycin. 
Assuming they are independent events the probability of resistance to more than one 
drug is the probabilities for each drug alone. The probabilities of  isoniazid and 
rifampicin resistance occurring in the same organism is 1 in 106, 1 in 108 respectively 
or 1 in 1014. 
 
 The bacterial population in a cavitary pulmonary lesion is estimated to be 109 
organisms. Therefore the bacterial population of these lesions is lightly to include a 
small number of mutants resistant to any single antituberculosis drug. Only very 
rarely will the population include a significant number of mutants resistant 
simultaneously to two or more drugs. Monotherapy with a single antituberculosis drug 
does not induce drug resistant mutants. But it suppresses the bacteria susceptible to 
that drug thereby selecting for mutants resistant to that drug. 
 
 Drug resistant tuberculosis occurs when there is a substantial increase in the 
proportion of the organisms that are resistant to one or more antituberculosis drugs. 
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There are two ways a patient can develop drug resistant tuberculosis. Acquired or 
secondary drug resistance occurs when the small numbers of drug resistant mutants 
are selected as a result of ineffective anti tuberculosis. In tuberculosis acquired drug 
resistance may appear after two weeks but more usually from one to four months after 
the start of therapy when the bacterial population is relatively large.  
 
 Primary drug resistance on the other hand occurs when the patient becomes 
infected with mycobacterium tuberculosis organism resistant to one or more drugs 
before the patient is treated with the drug in question. Primary drug resistance is not 
distinguishable clinically from acquired drug resistance except by history.  
 
 Initial drug resistance is an entity which includes all primary drug resistance 
and also concealed acquired resistance. This sort of  concealed acquired resistance 
will pose a major threat to the outcome of treatment. For example, the risk of relapse 
with isoniazid resistant organism increases by about 4 % per month or prior therapy, 
but upto 23 % of patients in one study treated for one month with isoniazid alone had 
isoniazid resistant organism. 
 
 In clinical practice a patient with tuberculosis is said to have drug resistant 
disease if that patients bacillary population consist of organism that would probably 
failed to respond treatment with drug concerned in normal dosage,  for example a 
dosage that will cause a response in patients infected with drug susceptible organism. 
  
 
13
PROPOSED THEORIES  
 
 Very little is known regarding the mechanism of the development of  drug 
resistance to various antituberculosis drugs. Of  the several theories put forward to 
explain the mechanism of development of drug resistance in micro organisms, three 
theories may be relevant to mycobacteria. These include  
1. Interference in uptake or penetration of the drug in to the bacterial cell. 
2. Development of insusceptible metabolic pathways. 
3. Destruction of drug. 
Using the 14C labeled isoniazid  Barclay et-al found that isoniazid resistant strains 
take up markedly less radioactive material than the susceptible strains. Youatt et-al 
confirmed these findings and suggested that the possible reason could be due to 
alteration in cell permeability. 
Factors Influencing the Development of Acquired Drug Resistance 
 INCREASED CHANCE 
1. Previous treatment of Tuberculosis. 
1.1 Greatest risk if treatment fails or disease relapses while patient 
is still on drugs. 
1.2 Significant risk if treatment was inadequate. This includes 
weak drug regiments and / or inappropriate duration. 
1.3 Treatment received while living in high tuberculosis incidence 
area. 
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2. Birth and / or  recent residence in a high tuberculosis incidence area. 
2.1 Particularly Asia, South and Central America and Africa. 
2.2 Certain localized areas within developed countries like 
Moscow, Latvia, Eistonia, Dominican republic, Ivory coast. 
These are called as hot zone for MDR TB by WHO. In India 
Places like Mizoram, Assam. 
2.3 The younger the age the greater the risk. 
 
3. Recent exposure to a known case of drug resistant disease. 
4. Infection with mycobacteria other than mycobaterial tuberculosis. 
 
 DECREASED CHANCE 
1. No previous treatment for tuberculosis. 
2. Birth and / or resistance in low tuberculosis incidence area -- the longer 
the less likely. 
3. Recent exposure to a known case of drug susceptible disease. 
 
MULTI DRUG RESISTANT TUBERCULOSIS (MDR TB) 
 MDR TB is defined as mycobacterium tuberculosis resistant atleast to 
isoniazid and rifampicin with or without resistance to other drugs. 
 
IMPLICATIONS OF DRUG RESISTANCE 
1. The most important implication of drug resistance (primary and / or 
acquired including MDR) is the outcome of the treatment. The 
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response in patients harboring multi drug resistant organism is very 
poor both in immuno competent and immuno compromised patients. 
2. The second and equally important implication is the spread and 
transmission of drug resistant tuberculosis. This is much more 
dangerous than the previous implication. The seriousness of the spread 
of  drug resistant tubercle bacilli is magnified several fold when 
patients involved are infected with HIV. 
GLOBAL PREVALENCE OF DRUG RESISTANT TUBERCULOSIS 
1. From 1982 to 1986 the CDC evaluated drug susceptibility of 
mycobacterium tuberculosis isolated from each 3730 new never treated 
patients. The overall resistance to atleast one drug was 8.8 % with 
isoniazid (5.3 %) and streptomycin (4.9 %) being the most common. 
2. CDC found that primary drug resistance varied by ethnicity with rates 
for Asians 14.8% and Hispanics 11.8% being lower for the whites 
4.9% than blacks 6.1%. 
PREVALANCE OF DRUG RESISTANCE IN INDIA 
1. In the1960s Indian Council of Medical Research (ICMR) conducted 
two nation wide surveys at 9 urban chest clinics in India. The results of 
the first survey showed the resistance level of 8.2 % to isoniazid alone 
5.8 % to streptomycin alone and 6.5 % to both the drugs. 
2. A decade later a study was conducted to assess the prevalence of 
primary drug resistance in Government chest Institute and chest clinic 
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of Government Stanley Hospital Chennai. The results of the study 
were almost similar to the earlier ICMR surveys and authors reported 
that prevalence of primary drug resistance has not risen during the span 
of ten years. 
3. In the early 1990s a retrospective study done at New Delhi showed a 
high level of primary drug resistance to isoniazid (18.5%) at a low 
level of rifampicin. 
4. Overall the prevalence rate of primary drug resistance to isoniazid as a 
single agent ranged from 6 to 13%, streptomycin as a single agent 
ranged from 1 to 5.8 % and rifampicin from 0 to 1.9 %. 
TRC STUDIES ON PREVELANCE OF PRIMARY DRUG RESISTANCE 
 It clearly shows that there was a gradual increase in the prevalence of primary 
drug resistance to anti tuberculosis drugs. For isoniazid the resistance rates ranged 
from 3 to 17 %, streptomycin from 3 to 13 % and rifampicin remains at 1 %. 
 
ACQUIRED DRUG RESITANCE 
 A study was conducted by the ICMR to compare the efficacy of short course 
chemotherapy with the conventional non short course chemotherapy in North Arcot 
District in Tamil Nadu. It was found that there was an increase in frequency of 
acquired drug resistance with 67% resistant to isoniazid 26 % to streptomycin and 
12% to rifampicin, 6% resistant to both isoniazid and rifampicin. A study conducted 
by the Institute of Thoracic Medicine Chennai showed that acquired resistance was 
63% out of which 23.5 % were resistant to single drug and 39.5 % resistant to more 
than 1 drug.  
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 The overall rates of acquired resistance to isoniazid ranged from 34.5 to 67% 
for streptomycin from 26 to 26.9 % and for rifampicin from 2.8 to 37.3 %. 
 
INITIAL DRUG RESISTANCE 
 Overall Initial resistance to isoniazid as a single agent ranges from 0.62 to 
13.2 % to streptomycin from 2.2 to 7 % and to rifampicin from 0 to 1.7 %. 
 
 
MULTI DRUG RESISTANCE 
 The rate of MDR TB in India is very low ranged from 0 to 6 %. Primary MDR 
TB was found to be less than or equal to 3.2 %. Acquired MDR TB is less than or 
equal to 6 % except in Gujarat where it is 18.5 %. 
 
 In a recent report from Institute of Thoracic Medicine Chennai on the 
prevalence of MDR TB among patients undergoing treatment for varying periods of 
time at 4 district Tuberculosis centers in Tamil Nadu showed that 20.3 % were found 
to be harboring. Majority of these patients are irregular and interrupted treatment 
owing to non availability of drugs. Overall MDR TB is around 13.3 % of all TB 
patients. 
 
EXTENSIVELY DRUG RESISTANT TUBERCULOSIS 
 A serious wake-up call for global health, Tuberculosis outbreaks in the 
developed world are newsworthy. However, in the developing world, where deaths 
from tuberculosis are common, it takes something exceptional for an outbreak to 
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attract much attention. In response to a recent report at the 16th international AIDS 
conference and to increasing South African media reports, the World Health 
Organization expressed concern about extensively drug resistant tuberculosis (also 
referred to as "XDR tuberculosis").  
 
 Among 536 culture confirmed cases of tuberculosis at a rural hospital in South 
Africa, 41% were multidrug resistant, defined as resistance to rifampicin and 
isoniazid (two key first line drugs). This is cause enough for concern as multidrug 
resistant tuberculosis has a worse outcome and its management is very difficult even 
in high resource settings. Even more alarming was that 53 (24%) of the isolates from 
multidrug resistant tuberculosis fulfilled the definition of extensively drug resistant 
tuberculosis namely, multidrug resistant tuberculosis that is also resistant to at 
least three of the six classes of second line agents. Such tuberculosis is virtually 
untreatable.  
 
 All patients in this outbreak who were tested were HIV infected, and 52 of the 
53 died after a median of just 25 days. In 90% of the isolates the same genetic 
fingerprint was present, indicating extensive recent transmission. Fifty six per cent of 
patients had previously been admitted to hospital, raising the likelihood of nosocomial 
transmission.  
  
 Outbreaks of infectious diseases are always more newsworthy if their 
implications extend beyond the local context, which is the case with extensively drug 
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resistant tuberculosis. For some years, such strains have been known to exist in Asia, 
North and South America, and Europe. In March this year, the Centers for Disease 
Control and Prevention and WHO reported a survey of over 17 000 tuberculosis 
isolates collected from around the world between 2000 and 2004. Overall, 2% of 
multidrug resistant strains were also extensively drug resistant, being most frequently 
found in eastern Europe, western Asia, and South Korea. Population based data from 
the United States, Latvia, and South Korea showed that 4%, 19%, and 15% 
respectively of multidrug resistant strains could be defined as extensively drug 
resistant.  
  
 The epidemiology and the limited genotypic data currently available indicate 
that this is not a single strain, but that extensively drug resistant strains are likely to 
have emerged in many different places and on multiple occasions. Paradoxically, this 
is both reassuring and alarming. It is reassuring in that the emergence of extensively 
drug resistant tuberculosis in more than one strain suggests that the mutations 
responsible are specific for drug resistance rather than reflecting a fundamental 
change in behaviour of the organism. This is nevertheless alarming because it also 
suggests that extensively drug resistant tuberculosis probably arises fairly regularly 
and is already disseminated.  
 
 Drug resistance to tuberculosis results largely from poorly managed care and 
control of the disease. Poor prescribing practices, low drug quality (or erratic supply), 
and suboptimal adherence can all contribute to this. Bacilli are subject to intense drug 
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selection, and exposure to mono-therapy predisposes to an accumulation of mutations 
that confer resistance. Hence optimal treatment includes four drugs to which the 
organism is sensitive, and a single drug should never be added to a failing 
regimen. In much of the world, routine culture and sensitivity testing is not 
available. Thus, where multidrug resistant tuberculosis emerges, inappropriate 
treatment regimens may lead to serial acquisition of resistance mutations, with 
potential for emergence of extensively drug resistant tuberculosis. Widespread use 
of second line tuberculosis drugs (such as quinolones for respiratory tract infections) 
may also contribute to the development of resistance. Thus, the emergence of 
extensively drug resistant tuberculosis should come as no surprise it was entirely 
predictable in the context of poor control practices.  
 
 The havoc that institutional transmission of multidrug resistant tuberculosis 
can wreak amongst HIV infected people was evident in the US in the early 1990s. The 
very modest actual rise in the incidence of tuberculosis that coincided with these 
outbreaks has now been reversed, albeit with extraordinary effort and cost. However, 
the huge potential for extensively drug resistant tuberculosis to further undermine 
control practices in communities in South Africa and elsewhere in the region is self 
evident and would be much more difficult to control. In some communities with an 
antenatal prevalence of HIV of 30%, annual notification rates for tuberculosis have 
already increased uncontrollably over the past 10 years, reaching 1500/100 000-a rate 
more than 250 times higher than rates in the US. Extensively drug resistant 
tuberculosis must now serve as a serious wake-up call. Although the potential 
consequences may be most grave in settings with a high prevalence of tuberculosis 
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and HIV, extensively drug resistant tuberculosis is nevertheless already a very serious 
development in many other parts of the world too. What response is needed? The 
global scale and molecular epidemiology of extensively drug resistant tuberculosis 
require urgent assessment, and laboratory capacity needs to be greatly increased 
within a network of sentinel sites. Control practices must be rigorously and effectively 
implemented. Increasing cure rates for tuberculosis through directly observed 
treatment short course (DOTS) is crucial. Detection rates for cases of tuberculosis 
need to be improved, highlighting the need for a new diagnostic test. Technologies 
that can determine the presence of drug resistance at the point of care are needed, as 
are new drug treatments. The DOTS-Plus strategy for treatment of multidrug resistant 
tuberculosis needs to be further developed for areas where the disease is established. 
Nosocomial transmission of tuberculosis is probably commonplace in the developing 
world, and simple, effective strategies to reduce such transmission need to be urgently 
implemented. More fundamentally, the emergence of extensively drug resistant 
tuberculosis is a reminder that tuberculosis needs massive broader commitment: the 
incompletely funded Global Plan to Stop TB demands political will and financial 
action. 
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MATERIALS AND METHODS 
 
 
 1. The study was conducted at Institute of Thoracic Medicine Chennai. 
 2. Patients who had reported with sputum positivity with the H/O  
  treatment under RNTCP with cat II and subsequently   
  failed/defaulted/relapsed were included in the study. 
 3. All of them were subjected to sputum AFB culture and sensitivity  
  studies. 
 4. Sensitivity pattern were evaluated with their previous ATT prior to  
  cat II. Total of 140 patients were included, 34 were excluded based on 
  the exclusion criteria. The study conducted during 2004 & 2005.  
  The remaining 106 patients were evaluated in this study. 
 5. It is a retrospective study cohort. The culture sensitivity obtained were 
  analyzed retrospectively. 
 
INCLUSION CRITERIA 
Patients who had reported with sputum positivity with history of treatment 
under RNTCP with Cat II and subsequently failed / defaulted / relapsed were included 
in the study. 
EXCLUSION CRITERIA 
The following were the exclusion criteria. 
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1. Those who had diabetes mellitus (18 patients) at the time of enrollment 
into the study. 
2. Those who had HIV positivity (6 patients) at the time of enrollment 
into the study. 
3. Those patients whose AFB sputum cultures were contaminated (10 
patients). 
SPUTUM FOR AFB CULTURE AND SENSITIVITY 
 Sputum for AFB culture and sensitivity for 106 patients who were included in 
the study were done at the Tuberculosis Research Centre (TRC). 
  
PROCEDURE 
 Cultures were put up by single step culture technique using transport medium. 
 
PREPARATION OF TRANSPORT MEDIUM 
 This consist of TRISODIUM PHOSPHATE (Na3PO412H2O) 200 gms, 
Ammonium sulphate – 5 gms magnesium sulphate -500 mgs, Ferric ammonium 
Citrate – 250 mgs and distilled water 100 ml.. These chemicals were dissolved in 
water by heating, the solution was filtered and sterilized at 121 degree centigrade for 
about 15 minutes. The medium termed transport medium was distributed in 10 ml. 
quantity in to sterile screw cap Mc Cartney bottles and stored at room temperature. 
These bottles were supplied to the patients who were instructed to open them and 
expectorate sputum in to them. 
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SINGLE STEP CULTURE TECHNIQUE 
 Sputum was either mixed with two volumes of transport medium or collected 
in to Mc Cartney bottles as described above. The sputum transport medium mixture is 
centrifuged and allowed to stand overnight at room temperature on the following 
morning the supernatant fluid was decanted and one loop full of the deposit was 
inoculated on to the slope of Lowenstein Jensen (LJ) medium which was then 
incubated at 37 degree centigrade for 6 weeks. 
 
CULTURE READING 
 Culture was read at the end of every week for six weeks and growth typical of 
mycobacterium tuberculosis were noted. It is rough and tough white colored colonies 
sometimes like cauliflower appearance and it is graded as follows. 
 
  + + +     Confluent Growth 
  + +     Innumerable Discrete colonies  
  +     20 – 100 Colonies 
  Less than 20 colonies    Actual Number 
 Cultures that did not show any growth at the end of 8 weeks were declared as 
negative. All the positive cultures were tested for sensitivity to streptomycin, 
isoniazid, rifampicin, ethambutol, ethionamide, ofloxacin, and kanamycin.  
 The sensitivity pattern was done using absolute concentration method and 
resistance ratio method.  
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Absolute concentration method  
 Absolute concentration method test determines the minimal inhibitory 
concentration of isoniazid and streptomycin by the inoculation of control media and 
the drug containing media with a carefully controlled inoculum of mycobacterium 
tuberculosis. Media containing several sequential two fold dilutions of each drug are 
used. Resistance is indicated by the lowest concentration of drug which will inhibit 
growth defined as 20 colonies or more at the end of 4 weeks.  
 
Resistance Ratio Method 
 Resistance Ratio Method is a variant of absolute concentration method was 
first introduced by Mitchison to prevent variation of MICs when a strain of 
mycobacterium tuberculosis was tested on different batches of medium because of 
fluctuation in the degree of inactivation of streptomycin by the egg components of the 
medium during inspissation.  
 
 Intra laboratory and inter laboratory variations between media batches with 
regard to the drug susceptibility testing of streptomycin and other drugs were 
corrected after comparing the resistance of the wild strain with reference strain H37RV 
tested in parallel on the same batch of the medium. 
 
 Growth is defined as presence of twenty or more colonies at the end of four 
weeks. The resistance ratio is defined as minimal concentration inhibiting the growth 
of the test strain divided by the minimal concentration inhibiting the growth of the 
standard susceptible strain in the same set of tests. A culture showing a resistance 
 
27
ratio of 2 or less is defined as susceptible while a ratio of 8 or more denotes 
resistance. 
 
RAPID METHODS FOR THE DETECTION OF DRUG 
RESISTANCE IN MYCOBACTERIUM TUBERCULOSIS 
 
1. Radio Metric Methods – BACTEC 
2. Luciferase reporter Assay  
3. Mycobacteria Growth Indicator Tube 
4. Rapid Genotype Based Novel Techniques  - using polymerase chain 
reaction (PCR) 
5. Restriction Fragment Length in Polymorphism Analysis (RFLP) 
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   RESULTS 
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RESULTS 
 
 
TABLE 1  
 AGE – SEX DISTRIBUTION 
Male Females Total Age 
group 
years Patients % Patients % Patients % 
Upto 20  1 14.28 6 85.72 7 6.60 
21 – 40 36 67.92 17 32.08 53 50.00 
41-60 34 87.18 5 12.82 39 36.80 
> 61 7 100 0 0 7 6.60 
Total 78 73.58 28 26.42 106 100.00 
 
1. Total number of patients studied were - 106. 
2. Among them male patients were  - 78. 
3. Females were – 28. 
4. More number of patients were in the age group of 21 to 40. 
5. Total number of patients in the above group were 53. 
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Sex Distribution - Male  
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Sex Distribution - Female 
85.72
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TABLE 2 
Drug Resistance Profile of the study population: 
 
Category II status Number MDR % of MDR One or more drug resistance Percentage 
Failure 90 78 86.66 12 13.33 
Relapse after cat II 1 1 100 --  
Treatment after 
default from cat II 
15 10 66.66 5 33.33 
Total 106 89 83.96 17 16.04 
 
1. Among the 106 patients who were included in the study 90 have failed 
with Cat II and subsequently 78 have become MDR TB patients which 
accounts for 86.66 % 
2. 15 patients were in the treatment after default group after Cat II. Most of 
them have defaulted atleast two times after initiating Cat II. Among the 15, 
10 have become multi drug resistant tuberculosis patient which accounts 
for 66.66 %. 
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3. Among the patients who failed with Cat II the remaining 12 non MDR TB 
patients had resistance to one or more other drugs. 
 
 
4. Among the patients who were in the treatment after default group 
following Cat II the remaining 5 non MDR TB patients had resistance to 
one or more other drugs. 
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TABLE 3 
Cat II Failure – Non MDR TB patients drugs resistance profile: 
Drugs No. of Patients 
H 3 
S, R 1 
R, E, ETH, KAN 1 
S, H 3 
H, ETH 2 
H, E, ETH 2 
 
 
 
 
1.  All patients had resistance to atleast one of the primary drugs. 
2.  Three patients had reserve drug resistance namely ETH & KAN. 
3.  All the patients had either INH or Rifampicin resistance. 
 
Post cat II treatment after default non – MDR ( 5 ) 
1.  4 of them had only INH resistance.  
2.  1 had both INH & ETH resistance. 
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TABLE 4  
 
 
 
Cat I outcome of these 106 patients. 
Outcome No. of patients No. of MDR Percentage 
Failure 75 65 86.66 
Defaulter 15 11 73.33 
Cure followed by 
relapse 
16 13 81.25 
Total 106 89  
 
 
 
 
1. Among the 106 patients studied 75 patients have failed with Cat I. and 
subsequently 65 have become MDR TB patients which accounts for 
86.66 %. 
2. Among the 106 patients 15 have defaulted and 11 have subsequently 
have become MDR TB patients. 
3. Among the 16 relapsed cases 13 have become MDR TB patients.       
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TABLE 5 
 
 
Category II Failure & Defaulter Rates – National Figures 
 
 
 
YEAR 2003 2004 
NO OF RETREATMENT 
CASES 
 
112304 
 
150297 
FAILURE % 6 6 
ACTUAL NO. FAILURE 6738 9018 
DEFAULTER % 15 15 
ACTUAL NO. DEFAULTER 16846 22545 
 
1. The actual number of cases registered under Cat II is showing an increasing 
trend. 
2. The actual number of cases failed with Cat II in terms of absolute number has 
also increased. 
3. Percentage of Defaulters in terms of absolute number has also increased. 
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DISCUSSION 
 
 
 
 Information on the prevalence of the drug resistance is essential for the 
successful formulation of treatment policies in our country. 
 
 Sputum positive re-treatment cases constitute 25% of all smear positive cases 
registered under RNTCP. Our country is progressing towards 100% implementation 
of RNTCP. In this background as each year progresses the no. of cases put on cat I  as 
well as cat II are showing an increasing trend. Those cases who fail with cat II as well 
as those who default from cat II add to the newly detected cases each year. 
 
 We are in need of intermediate reference laboratories for carrying out drug 
sensitivity testing for tackling cat II failure and treatment after default groups in every 
state. Those cases thus identified require reserve line of drugs which are costlier as 
well as not freely available.  
 
 In this study among cat II failure the prevalence of MDR TB to the tune of 
87% is a cause for concern. Hence advising culture and sensitivity at an appropriately 
early state i.e ) at the time of cat I failure are atleast when the sputum conversion does 
not occur at the end of intensive phase will help to diagnose multi drug resistance or 
drug resistance patients under program condition. It will enable us to give the correct 
line of management either before or at the time of declaring a patient as cat II failure. 
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RELATED STUDIES 
1. INFLUENCE OF DRUG SUSCEPTIBILITY ON TREATMENT 
OUTCOME AND SUSCEPTIBILITY PROFILE OF ‘FAILURES’ TO 
CATEGORY II REGIMEN. 
This study was done by Tuberculosis Research Centre Chennai. From May 1999 
through December 2004, a total of 697 smear-positive patients were started on 
re-treatment with CAT-II regimen. The proportion of smear-positive re-
treatment cases to the total smear-positive cases ranged from 24.5% in 1999 to 
22.8% in 2004. The 697 patients included - 32% cases of ‘Relapse’, 20% 
‘Failure’ and 47% ‘Treatment After Default’ cases. 
 
 Treatment outcome according to ‘type’ of cases Of the 697 smear-
positive patients registered to CAT-II regimen, 572 patients whose treatment 
outcome was available by December 2004 are included in the analysis. Of the 
total 572 cases, 238 (42%) had a successful treatment outcome (cure-41%, 
treatment completed-1%) and 240 (42%) defaulted. ‘Relapse’ cases had a 
significantly higher cure rate (51%) compared to ‘Failure’ and TAD cases 
(p<0.01). Fifty-two (9%) patients failed to the re-treatment regimen; 14%  
(15 of 111) among ‘Failures’, 8% (15 of 187) among ‘Relapses’, and 8% (22 
of 274) among ‘TAD’ cases. However the difference was not statistically 
significant. The time at which patients defaulted was available for 219 out of 
the total 240 from the treatment cards and 49% defaulted within the first 3 
months of treatment. The rate and time of default were almost similar in all 
types of patients. Forty-one (7%) patients died during the course of the 
treatment. Of the 37 patients for whom information is available, 70% died 
within 3 months of starting treatment.  
 
39
  The proportion of smear-positive retreatment cases in this DOTS 
 implemented area, over a period of 5 years, from 1999 through 2004, did not 
 show any significant changes and it ranged from 24.5% in 1999 to 22.9% in 
 2004.  Among the retreatment TB patients, nearly 50% constituted patients 
 who came for  re-treatment after defaulting to the previous regimen. 
 The low success rate (42%) to the CAT-11 regimen was mainly due to the 
 high default (42%) during treatment. If all these defaulted patients (240) 
 also had been regular for treatment, the treatment success would have been 
 72%. Another important finding revealed in this analysis is that the prevalence 
 of drug resistance (non-MDR as well as MDR) was almost similar initially and 
 at the time of failure. Development of resistance to Rifampicin among patients 
 who failed to CAT II  regimen was low (2 patients with initial resistance to H 
 emerged resistance to R.) 
 
 High default rate (42%) was the major reason for the low cure rate in  this 
area. Default rate was similar in all groups of patients, irrespective of the type 
of patients or their drug resistance pattern. The success rate (42%) for the re-
treatment cases in this report is significantly low compared to the national  
average of around 70% 
 
2. IS IT WORTH TREATING CATEGORY I FAILURE PATIENTS WITH 
 CATEGORY II REGIMEN? 
 
 
 
  This study was done by Tuberculosis Research Centre Chennai. In all, 1463 
 study patients were registered between May 1999 and December 2002. 
 Sputum was collected from 1395 (95%) and drug susceptibility profile was  
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 available for 1226 patients, 158 were negative on culture and 11 were 
 contaminated. Of the 1226, 1094 (89%) had organisms susceptible to H and 
 R, 111 (9%) resistant to H, 16 (1.3%) to H and R (Multi-Drug Resistant) and 5 
 (0.4%) to R alone. Treatment outcome of the 1463 patients was as follows: 
 1117 (76%) had a successful treatment outcome, 212 (14.5%)had defaulted, 
 58 (4%) died, 74(5%) were declared to have failed while two were transferred 
 out. 
 
  Under programme conditions, patients are declared ‘failed’ on Cat I 
 regimen if smears become positive at 5-month or more after starting treatment. 
 In our series, of the 74 patients declared to have ‘failed’, MDR TB (organisms 
 resistant to H and R) was seen among 17% justifying the use of Cat II regimen 
 for failures of Cat I treatment for the remaining 83% of patients. Thus, all 
 failures do not have MDR TB. A study from Vietnam had reported 80% of 
 Category I failure cases to have MDR TB. The regimen, 2SHRZ/6HE used for 
 treatment in Vietnam differed from the 2REHZ3/HR3 used in this programme. 
 In the study from Vietnam, emergence of drug resistance was considered only 
 for patients who had RFLP matching cultures at pre-treatment and at the time 
 of failure. A programme-based study from Malawi had reported that none of 
 the failures to  first line treatment with 6HE in the continuation phase 
 following an intensive phase of either 2SHRZ or 2HRZE3 had MDR TB.  
 
  In conclusion, our finding that nearly 80% of the ‘failures’ (as declared 
 in the programme, based on smear results), have organisms susceptible to R, 
 justifies the use of the currently recommended category II regimen for failures 
 
41
 of category I treatment. Close monitoring of these patients will be required to 
 identify failures early and if necessary, change of treatment can be 
 considered for those  patients who do not show any response to treatment 
 with Cat II regimen at 3-months.  
 
3. TIME TO ABANDON THE STANDARD RETREATMENT  REGIMEN WITH 
FIRST LINE DRUGS FOR FAILURE OF STANDARD TREATMENT 
This study was conducted in Vietnam. About 2901 new cases were registered 
and sputum samples were collected before initiating the treatment with Cat I 
and at that time of failure / relapse once again sputum samples were collected. 
Both the samples underwent culture and sensitivity and RFLP studies.  
 
 80 % of the failure cases in Cat I were MDR TB patients. Therefore 
culture and sensitivity at the end of intensive phase if sputum remains positive 
or at failure in Cat I is recommended. 
 
 Cure rate of failure cases treated with re-treatment regimen of 
first line drugs in Vietnam was 46% and Peru 47%. Therefore who fail the 
treatment regimen with the first line drugs and receive poor re-treatment 
regimen based on same drugs will most likely fail. 
 
4. DRUG SUSCEPTIBILITY AMONG FAILURES AND RELAPSES CASES OF 
TUBERCLOSIS : IS STANDARD RE-TREATMENT REGIMEN ADEQUATE 
  This study was conducted in Vietnam, objective of the study 
 was to determine acquired drug resistance among failure and relapsed cases 
 after treatment of new smear positive tuberculosis patients. 
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  Conclusion of the study showed that primary drug resistance was a 
 strong risk factor for failure and relapse and for acquiring further resistance. 
 As 80 % of failure cases had MDR the standard re-treatment regimen appears 
 inadequate for failure cases in control programs with a very high cure rate 
 among new cases.  
 
5. OUTCOME OF TUBERCULOSIS RETREATMENT IN ROUTINE 
CONDITION IN COTONOU, BENIN 
  The aim of the study was to evaluate the patient characteristics and 
 outcome of Tuberculosis re-treatment regimen in a well functioning national 
 tuberculosis program. 
  It is a retrospective, register based study. All smear positive pulmonary 
 tuberculosis patients put on re-treatment regimen (CAT-II) were included.  
 Among the 8103 patients registered 642 put on re-treatment. This study was 
 done during 1992 – 2001.  
  Among the 642 patients put on re-treatment regimen 236 patients were 
 studied. Among them 113 had relapse 84 failure 39 return after default. Most 
 of the relapse 57 % and return after default 72 % were put on re-treatment 
 within one year. Overall re-treatment results were satisfactory with 78 % 
 success, 3 % failure and 21 % defaulter.  
  The conclusion of the study was that standard re-treatment regimen 
 was effective in Cotonou probably because the NTP is functioning well, there 
 are no drug shortages, drug taking is strictly supervised and good treatment 
 plan is followed. 
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CONCLUSION 
 The drug resistance profile among patients reporting Institute of Thoracic 
Medicine Chennai with sputum positivity after taking CAT II regimen under 
RNTCP and either failed / relapsed or defaulted from CAT II were evaluated and 
the following conclusions were made. 
1. Possibility of MDR TB is found to be 87% when a patient fails 
with cat II under RNTCP. 
2. Possibility of having MDR TB is to the tune of 90% when a patient 
fails with CAT II preceded by a failure in CAT I 
3. It is preferable to have culture and sensitivity study when the 
patient fails with cat I or atleast when the patient does not get 
converted at the end of intensive phase of cat II. 
 
By doing so unnecessary time delay in initiating appropriate reserve regimen can be 
avoided and can prevent the diseases transmission to others.  
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